The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data.
The post Investor Caution Leads to Dip in Biotech Financings, GlobalData Report Shows appeared first on MedCity News.
